BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Lundbeck Inc. (LUN.CO) and Otsuka Pharmaceutical Co., Ltd. Take Alcohol Drug to Japan in $136 Million+ Pact


10/31/2013 7:27:20 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Lundbeck has expanded its alliance with Otsuka Pharmaceutical Co to include development and commercialisation of the alcohol dependence drug Selincro in Japan. Selincro (nalmefene) was approved by the European Medicines Agency earlier this year and the two partners say the first Phase III study for Japan will be initiated during 2014. Under the terms of the agreement, Lundbeck will pocket a 50 million euro fee, finance the development costs and have an option to co-promote in Japan.

Help employers find you! Check out all the jobs and post your resume.



   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES